ImmunoGen Has Lots Of Room For Stock Appreciation
Seeking Alpha,
ImmunoGen ( IMGN ) is a small biopharmaceutical company (market cap of $174.62 million) that uses antibody-drug conjugate (ADC…
A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma
Overview of attention for article published in British Journal of Haematology, March 2016
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (91st percentile)
-
High Attention Score compared to outputs of the same age and source (99th percentile)
Readers on
- mendeley
- 52 Mendeley